Grinding as a Stage of Drugs Manufacturing

In the manufacture of dosage forms of the powder, in addition to mixing and pressing, the operations of grinding, granulation and tableting are carried out.

The grinding of the drug is used to achieve homogeneity of mixing, elimination of large constituents in clumps and glued materials, improving technological and biological effects.

Grinding of powders contributes to a certain increase in strength and the number of contacts between particles and, as a result, to the formation of strong conglomerations. The coal industry uses the method of running durable granules of the powder.

Fine grinding of medicinal powders, despite the possible advantages of bioavailability, has not found application, with the exception of certain cases. It is widespread use in the technology of solid dosage forms’ manufacturing. It happens due to the fact that the crystal is a rigidly formed structure with minimal free and high internal energy.Drug manufacturing

Therefore, for its destruction, a significant external effort is required. At the same time, in the system of crystals simultaneously with grinding, friction increases, which reduces the applied external load to values that can only cause elastic or slight plastic deformation. Therefore, the grinding effectiveness decreases rapidly especially in crystalline substances with a high melting point.

A certain amount of the liquid phase is injected into the milled powder to increase plastic deformation.

An increase in the free energy of crystals during grinding can serve as a cause of the mechanochemical destruction of preparations and a decrease in their stability during storage.

Grinding of highly plastic materials with low melting points, such as lubricating substances, can lead to a significant increase in their effectiveness in the tablets’ manufacturing.

Some soft conglomerations of powders can be eliminated by filtration or wiping them through perforated plates or filtrates with a certain size of holes. In other cases, filtration is an integral part of grinding to obtain a mixture with a specific particle size distribution.

Grinding is also used for processing substandard granules and tablets.

A number of devices with various working bodies are used to implement the cut of powders and granules. Often grinding units are included in the complex of equipment for processing the initial substances and final products – granules (granulators, mixers, granulators, classifiers, etc.).

The choice of the optimal technological scheme for the production of tablets depends on the physicochemical and technological properties of medicinal substances, their amount in the composition of the tablet, resistance to environmental factors, etc.

Pharmacy News

Who Regulates the Cost of Drugs and Why Can’t They Be Dispensed Free of Charge?

In social networks, you can often find calls to raise funds for medicines for a sick child. A logical question arises: why won’t the state save this child by paying for the necessary drugs? We figured out how drug prices are determined, who should regulate them, and why pharmaceutical companies do not distribute drugs to save lives. How are drug prices determined? Manufacturers of medicines and pharmacies participate in the…

Detecting Fake Medicines | Trust Pharmacy Guide for Consumers

New drugs are invented every year. Their total cost is approximately $27 million – about 1% of the entire pharmaceutical market. Thus, the risk of buying a counterfeit from a pharmacy is very small. However, there is also a factory defect or poor-quality drugs that simply will not cure a patient. MLST Trust Pharmacy has been working in the pharmaceutical market for over 10 years and has close cooperation with…

What Is A Conventional and Online Pharmacy in the USA and Canada?

Retailing pharmaceuticals in the USA is a rather huge market. Most pharmacies in the United States are private. Every person can buy absolutely any product in the US pharmacy, even if this does not apply to medications. American pharmacies occupy a fairly large area, consist of two zones – the zone for dispensing drugs and a self-service zone. In the states, almost all medications are sold only by prescription. Only…

Laureate and ARIUS Cooperation

Princeton, NJ and Paris, France, March 27, 2008: Laureate Pharma, Inc., a full-function facility of biopharmaceutical development and protein manufacturing, claimed nowadays that it has signed a contract with Cytheris SA, a clinical phase of biopharmaceutical facility oriented on trials and development of new treatment for immune stimulation. According to the contract, Laureate will produce Cytheris’ lead product candidate, Interleukin-7 (IL-7), a complete glycated recombinant human protein and crucial growth-stimulating…

Laureate Announces Second Manufacturing Agreement with Cytheris

Princeton, NJ and Paris, France, March 27, 2008: Laureate Pharma, Inc., a full-function facility of biopharmaceutical development and protein manufacturing, claimed nowadays that it has signed a contract with Cytheris SA, a clinical phase of biopharmaceutical facility oriented on trials and development of new treatment for immune stimulation. According to the contract, Laureate will produce Cytheris’ lead product candidate, Interleukin-7 (IL-7), a complete glycated recombinant human protein and crucial growth-stimulating factor for…

Laureate Pharma Agreement with Alopexx Pharmaceuticals

Laureate To Manufacture Alopexx’s Product Candidate On April 10, 2008, Laureate Pharma, Inc., a large company engaged in biopharmaceutical development and protein production reported that it has concluded a contract manufacturing agreement with Alopexx Pharmaceuticals on the production of Alopexx’s mAb F598 antibody under cGMP conditions. This antibody will be used in clinical trials and also for fighting Staphylococcus aureus infections. The details of the agreement were not announced. “We are happy that Laureate…

Laureate Pharma Company – Press Release

FOR IMMEDIATE RELEASE Laureate Pharma Launches New Contract Manufacturing Venture Company offers services for development and manufacture of biopharmaceuticals and sustained-release products Princeton, NJ – May 21, 2002 – Laureate Pharma Company announces the launch of contract manufacturing services at its two sites in New Jersey. Biopharmaceutical development and manufacturing services will be provided at a cGMP manufacturing facility in Princeton, NJ. Services related to sustained release microsphere products will…

Laureate Pharma Extends its Agreement with Cytogen for Manufacture of PROSTASCINT®

Princeton, NJ – October 25, 2006: Laureate Pharma, Inc. announced today that it has renewed its agreement with Cytogen Corporation for the cGMP manufacture of ProstaScint®, Cytogen’s proprietary monoclonal antibody immunoconjugate that is used for imaging in patients diagnosed with prostate cancer. Under the agreement, Laureate will provide cGMP protein production, purification, conjugation of Cytogen’s proprietary linker chelator and aseptic filling services to support Cytogen’s commercial ProstaScint® requirements. Terms of…

Laureate Pharma & DrugAbuse Sciences – Press Release

FOR IMMEDIATE RELEASE Laureate Pharma and DrugAbuse Sciences Announce Commercial Manufacturing Services Agreement. Princeton, NJ – June 24, 2002 – Laureate Pharma L.P. and DrugAbuse Sciences, Inc. announce the initiation of a contract manufacturing agreement related to a sustained release microsphere product. Under the agreement, Laureate Pharma will provide manufacturing services for DrugAbuse Sciences’ Naltrexone Depot product, currently in clinical trials. Terms of the agreement were not disclosed. “We are…

LAUREATE PHARMA COMPLETES SALE OF TOTOWA, NJ OPERATIONS TO DISCOVERY LABORATORIES FOR $16.0 MILLION

Laureate’s Bioprocessing Facility at Princeton, NJ to be Expanded Princeton, NJ – January 3, 2006 – Laureate Pharma, Inc., a wholly-owned subsidiary of Safeguard Scientifics, Inc. (NYSE: SFE), announced today that it had completed the previously announced sale of its Totowa, NJ operations to Discovery Laboratories, Inc. (NASDAQ: DSCO) for $16.0 million in cash. Laureate Pharma, a provider of bioprocessing services to pharmaceutical and biopharmaceutical companies, conducts its principal operations…

Laureate Biopharma Appoints Ann M. Daus, Ph.D. Vice President, Quality

– Leads implementation of Laureate’s strategic quality plan – PRINCETON, N.J., March 16, 2011 — Laureate Biopharmaceutical Services, Inc., a full-service biopharmaceutical contract development and manufacturing organization, today announced the appointment of Ann M. Daus, Ph.D, as Vice President, Quality. Dr. Daus will lead the implementation of Laureate’s strategic quality plan, recruit new leaders to supplement the quality management team, lead the strategic expansion of testing services and improve companywide…

Laureate Pharma Honored as Emerging Life Sciences Company of the Year

Laureate recognized for its business growth, leadership team and service innovation by the Eastern Technology Council Princeton, NJ, November 20, 2008: Laureate Pharma, Inc., a full-service biopharmaceutical development and protein production company, today announced that it has been named the “Emerging Life Science Company of the Year” by The Eastern Technology Council, the largest technology and life sciences trade association in the greater Philadelphia, PA region. The company was honored…